This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Avadel (AVDL) This Earnings Season?
by Zacks Equity Research
On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.
What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?
by Zacks Equity Research
During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.
What's in Store for Aytu BioScience's (AYTU) Q3 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.
Will Gilead (GILD) Beat Q1 Earnings Despite Coronavirus Mayhem?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance along with updates on experimental coronavirus treatment, when Gilead (GILD) reports first-quarter 2020 results.
Is a Beat in Store for Abeona (ABEO) This Earnings Season?
by Zacks Equity Research
Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.
Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis
by Zacks Equity Research
The FDA confers a Fast Track status on Alnylam's (ALNY) RNAi therapeutic vutrisiran for treating adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Alnylam's $2B Deal With Blackstone to Boost Drug Development
by Zacks Equity Research
Alnylam (ALNY) and Blackstone sign a collaboration deal per which Blackstone will invest up to $2 billion in Alnylam. The funds will support accelerated development of Alnylam's pipeline.
Alnylam (ALNY) Completes Rolling Submission of Lumasiran NDA
by Zacks Equity Research
Alnylam (ALNY) completes rolling submission of the NDA for lumasiran seeking approval for kidney disease, primary hyperoxaluria type 1. The EMA accepts MAA for lumasiran for the same indication.
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Glaxo to Buy Stake in Vir Biotech, Signs Coronavirus Deal
by Zacks Equity Research
Glaxo (GSK) set to invest $250 million in Vir Biotechnology. Vir's stock soars.
Why Is Alnylam (ALNY) Down 7% Since Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus
by Zacks Equity Research
Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners
by Manaswita Ghosh Dutta
U.S. lawmakers' deal to find a vaccine for tackling the coronavirus stands to benefit the healthcare industry.
Alnylam's Givlaari Gets Approval in Europe for Rare Disease
by Zacks Equity Research
Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
by Zacks Equity Research
The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.
Pfizer's Cardiomyopathy Drug Vyndaqel Gets Approval in Europe
by Zacks Equity Research
Pfizer's (PFE) Vyndaqel gets approval in Europe and becomes the first therapy approved to treat ATTR-CM in the continent.
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -9.78% and 0.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA
by Zacks Equity Research
The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
by Zacks Equity Research
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
Alnylam Stock Up More Than 61% YTD on Pipeline Progress
by Zacks Equity Research
Shares of Alnylam (ALNY) rise on significant pipeline progress.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for EUSA